The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: A phase 1 study in advanced solid tumor malignancies.
 
Rahul Raj Aggarwal
Research Funding - Janssen; Novartis; Sanofi
 
Scott Thomas
No Relationships to Disclose
 
Jennifer A. Grabowsky
No Relationships to Disclose
 
Armand Harb
No Relationships to Disclose
 
Jim Leng
No Relationships to Disclose
 
Anne Reinert
No Relationships to Disclose
 
Ilaria Mastroserio
No Relationships to Disclose
 
Thach-Giao Truong
No Relationships to Disclose
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)